Histone cluster 2 H2AA3 Inhibitors
Chemical inhibitors of Histone cluster 2 H2AA3 function primarily by disrupting its role in chromatin architecture and gene regulation through the mechanism of histone deacetylase (HDAC) inhibition. These inhibitors, including Panobinostat, Romidepsin, Entinostat, Belinostat, Givinostat, Chidamide, Valproic Acid, Mocetinostat, Tacedinaline, and Quisinostat, all act to increase the acetylation levels of Histone cluster 2 H2AA3. This hyperacetylation affects the protein's ability to bind to DNA, leading to a less compact chromatin structure, which is critical for the regulation of gene expression. For example, Panobinostat and Romidepsin selectively inhibit HDAC, causing a rise in acetylation levels of Histone cluster 2 H2AA3, which disrupts its capacity to participate in chromatin condensation and gene silencing effectively.
Further, Entinostat and Belinostat work by targeting the deacetylation process specific to histones, including Histone cluster 2 H2AA3, thereby interfering with the histone's function in chromatin remodeling. This interference with chromatin structure is critical because it directly inhibits the protein's normal role in the cell. Givinostat and Chidamide, through their HDAC inhibitory activity, lead to an elevated acetylation state of Histone cluster 2 H2AA3, which impedes the histone's capacity for DNA binding and chromatin formation. Valproic Acid, a broader spectrum HDAC inhibitor, and Mocetinostat both induce a similar hyperacetylated state in Histone cluster 2 H2AA3, which hinders the histone's ability to compact chromatin efficiently. Lastly, Tacedinaline and Quisinostat heighten acetylation levels of Histone cluster 2 H2AA3, thus disrupting the normal functions of the histone in maintaining chromatin architecture and regulating gene activity within the cell nucleus.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is a potent histone deacetylase inhibitor that can affect Histone cluster 2 H2AA3 by increasing its acetylation levels. Enhanced acetylation disrupts its normal deacetylase-mediated function, inhibiting chromatin compaction. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin is a selective inhibitor of histone deacetylase, which causes an increase in acetylation of Histone cluster 2 H2AA3. This modification impairs the histone's capacity to participate effectively in chromatin condensation and gene silencing. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat is a benzamide histone deacetylase inhibitor that targets the acetylation status of histones, including Histone cluster 2 H2AA3. It inhibits the deacetylation process, thereby interfering with the histone's chromatin remodeling function. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat, a histone deacetylase inhibitor, functions by increasing the acetylation state of Histone cluster 2 H2AA3, which diminishes its DNA binding affinity and inhibits its role in chromatin compaction and transcriptional repression. | ||||||
ITF2357 | 732302-99-7 | sc-364513 sc-364513A | 5 mg 50 mg | $340.00 $1950.00 | ||
Givinostat is a histone deacetylase inhibitor that can cause hyperacetylation of histones like Histone cluster 2 H2AA3. Hyperacetylation impairs the histone's ability to maintain chromatin structure, thus inhibiting its functional role. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $62.00 $250.00 $1196.00 | ||
Chidamide is a benzamide chemical that inhibits histone deacetylases, leading to increased acetylation of Histone cluster 2 H2AA3. This increased acetylation inhibits the histone's function in nucleosome assembly and gene expression regulation. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid, a short-chain fatty acid, is a histone deacetylase inhibitor that induces hyperacetylation of histones including Histone cluster 2 H2AA3. This alteration in acetylation status hinders the histone's ability to compact chromatin effectively. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat is a histone deacetylase inhibitor that elevates the acetylation level of Histone cluster 2 H2AA3, leading to a reduction in its ability to form a condensed chromatin structure, thus inhibiting its structural function. | ||||||
CI 994 | 112522-64-2 | sc-205245 sc-205245A | 10 mg 50 mg | $99.00 $536.00 | 1 | |
Tacedinaline is a histone deacetylase inhibitor that increases the acetylation of histones like Histone cluster 2 H2AA3. This impedes the histone's capacity for DNA binding and chromatin formation, inhibiting its function in the cell. | ||||||
JNJ-26481585 | 875320-29-9 | sc-364515 sc-364515A | 5 mg 50 mg | $321.00 $1224.00 | ||
Quisinostat is a potent inhibitor of histone deacetylases that raises acetylation levels of Histone cluster 2 H2AA3. The resulting hyperacetylation disrupts the histone's normal functions in chromatin architecture and gene regulation. | ||||||